Quick Facts :

■	Founded in December 1999
■	Certified as a 'Venture Company' by the Small and Medium Business Administration in July 2000
■	Opened Japanese and U.S. Office in July 2001
■	Registered a domestic patent for INM176 as 'a dementia prevention and curing substance' in April 2002
■	Signed a supply contract for INM176 with Seltzer Chemicals Inc. in April 2002
■	Certified as a 'Venture Company of New Technology' by the Small and Medium Business Administration in May 2002

Scigenic works towards maximizing shareholders value by extracting source technology related to the development of new medicines with high early-stage success and marketability through investment in R & D. Through our global network, we strive to for success in the transfer of life science source technology in the pre-product stage.

The above table shows our financial decision making process for each project. The holding company raises funds for each project's R&D after receiving the patent, establishes its subsidiary for each project according to the contract researcher. The holding company then begins the process of seeking a potential buyer of the new technology, and provides them with evaluative information such as the scientific data and market surveys. When the technology transfer is complete, the profit is distributed to the investors and holding company while the researcher receives compensation from the holding company.

Scigenic advances the commercialization of the source technology by supporting the development of the surrounding technology. We are also increasing the business value of source technology via international patent surveys, applications and market surveys, along with market-focused R&D management.
All these factors contribute to the 'know-how for success' of Scigenic. Current projects in development include drugs for Alzheimer's disease, ischemic stroke, hypertension, hyperlipidemia, senile arthritis and pain killers.

Scigenic is devoted to developing technologies for health care products including new medicines to achieve its goal of becoming a leading global enterprise in the life science field. By linking our technological and financial goals, and by gathering professional know-how, we are working towards commercialization of these products. Our strengths lie in our cooperative relationship with both the academic and industry and our technological marketing experience.